Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class ASSE: 600671

Announcement on Reply to Letter of Supervision and Inquiry of 2025 Annual Report

· Issued by Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A via Shanghai Stock Exchange
Announcement on Reply to Letter of Supervision and Inquiry of 2025 Annual Report

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Earlier from Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A

All Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A news releases